![](https://www.fedaiisf.it/wp-content/uploads/2015/04/fedaiisf-ARCHIVIO-STORICO-780x450.jpg)
Thursday, June 12th, 2014 Live News.it
Aifa, stop at nine Geymonat drugs for "quality defect". The Italian Agency has banned the drugs as a precaution because there was less active ingredient in the medicines than what was declared. It is the same company that had seen the "seizure" of the suppositories produced for newborns because they were deemed unsafe. Yesterday, after the AIFA press release dated 5 September 2013, a new warning was launched for those who still had these 9 drugs at home and were using them, given that not all people, especially the elderly, benefit from mass media communications .
This is the press release that AIFA had issued in September: "It is a precautionary provision, issued by AIFA pending the results of the extraordinary checks in progress, (extraordinary checks which as a precaution have been arranged for all the packages in trade products of the company, for an estimated value of several million euros), adopted following constant monitoring actions aimed at reducing any risk, even if only hypothetical, for the health of patients, specifically linked to the possible presence of a quantity of active ingredient lower than that approved and indicated on the label.
THE LIST OF DRUGS - This is the list of drugs subject to a ban on use by AIFA:
ALVENEX 450 mg tablets 20 tablets and ALVENEX 450 mg powder for oral suspension 20 sachets. Indications: Symptoms attributable to venous insufficiency; states of capillary fragility
GASTROGEL 2 g/10 ml oral gel 30 sachets 10 ml . Indications: Gastric ulcer, duodenal ulcer; acute gastritis, symptomatic chronic gastritis; gastropathies from NSAIDs (non-steroidal anti-inflammatory drugs), reflux oesophagitis